Ebtesam Abdullah Al-Suhaimi

Prof. Dr. Ebtesam Abdullah Al-Suhaimi

Research & Innovation, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
EAEbtesam Abdullah Al-Suhaimi
Ebtesam Abdullah Al-Suhaimi
ASAdeeb Shehzad
Adeeb Shehzad
Adipose tissue is still regarded as a principle site for lipid storage and mobilizing tissue with an important role in the control of energy homeostasis. Additionally, adipose tissue-secreted hormones such as leptin, visfatin, resistin, apelin, omentin, sex steroids, and various growth factors are now regarded as a functional part of the endocrine system. These hormones also play an important role in the immune system. Several in vitro and in vivo studies have suggested the complex role of adipocyte-derived hormones in immune system and inflammation. Adipokines mediate beneficial and detrimental effects in immunity and inflammation. Many of these adipocytokines have a physiological role in metabolism. The uncontrolled secretions of several adipocytokines were associated with the stimulation of inflammatory processes leading to metabolic disorders including obesity, atherosclerosis, insulin resistance and type 2 diabetes. Obesity leads to the dysfunction of adipocytes andcorrelated with the imbalance of adipokines levels. In obese and diabetic conditions, leptin deficiency inhibited the Jak/Stat3/PI3K and insulin pathways. In this review, ample evidence exists to support the recognition of the adipocyte’s role in various tissues and pathologies. New integral insights may add dimensions to translate any potential agents into the future clinical armamentarium of chronic endocrine metabolic and inflammatory diseases. Functional balance of both adipocytes and immune cells is important to exert their effects on endocrine metabolic disorders; furthermore, adipose tissue should be renamed not only as a functional part of the endocrine system but also as a new part of the immune system.

22 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NANoor Alrushaid
Noor Alrushaid
Firdos Alam KhanFirdos Alam Khan
Firdos Alam Khan
EAEbtesam Abdullah Al-Suhaimi
Ebtesam Abdullah Al-Suhaimi
Abdelhamid ElaissariAbdelhamid Elaissari
Abdelhamid Elaissari
Traditional cancer diagnosis has been aided by the application of nanoparticles (NPs), which have made the process easier and faster. NPs possess exceptional properties such as a larger surface area, higher volume proportion, and better targeting capabilities. Additionally, their low toxic effect on healthy cells enhances their bioavailability and t-half by allowing them to functionally penetrate the fenestration of epithelium and tissues. These particles have attracted attention in multidisciplinary areas, making them the most promising materials in many biomedical applications, especially in the treatment and diagnosis of various diseases. Today, many drugs are presented or coated with nanoparticles for the direct targeting of tumors or diseased organs without harming normal tissues/cells. Many types of nanoparticles, such as metallic, magnetic, polymeric, metal oxide, quantum dots, graphene, fullerene, liposomes, carbon nanotubes, and dendrimers, have potential applications in cancer treatment and diagnosis. In many studies, nanoparticles have been reported to show intrinsic anticancer activity due to their antioxidant action and cause an inhibitory effect on the growth of tumors. Moreover, nanoparticles can facilitate the controlled release of drugs and increase drug release efficiency with fewer side effects. Nanomaterials such as microbubbles are used as molecular imaging agents for ultrasound imaging. This review discusses the various types of nanoparticles that are commonly used in cancer diagnosis and treatment.

27 October 2017 in Neurological Sciences
Verified
Journal Article
Closed access
MQMunibah Qureshi
Munibah Qureshi
EAEbtesam Abdullah Al-Suhaimi
Ebtesam Abdullah Al-Suhaimi
FWFazli Wahid
Fazli Wahid
OSOmer Shehzad
Omer Shehzad
ASAdeeb Shehzad
Adeeb Shehzad

16 July 2025 in Sensors
Verified
Journal Article
Open access
PDF file
Teodora SanislavTeodora Sanislav
Teodora Sanislav
GMGeorge Mois
George Mois
Sherali ZeadallySherali Zeadally
Sherali Zeadally
Silviu FoleaSilviu Folea
Silviu Folea
TRTudor C. Radoni
Tudor C. Radoni
EAEbtesam Abdullah Al-Suhaimi
Ebtesam Abdullah Al-Suhaimi
Food quality and safety are essential for ensuring public health, preventing foodborne illness, reducing food waste, maintaining consumer confidence, and supporting regulatory compliance and international trade. This has led to the emergence of many research works that focus on automating and streamlining the assessment of food quality. Electronic noses have become of paramount importance in this context. We analyze the current state of research in the development of electronic noses for food quality and safety. We examined research papers published in three different scientific databases in the last decade, leading to a comprehensive review of the field. Our review found that most of the efforts use portable, low-cost electronic noses, coupled with pattern recognition algorithms, for evaluating the quality levels in certain well-defined food classes, reaching accuracies exceeding 90% in most cases. Despite these encouraging results, key challenges remain, particularly in diversifying the sensor response across complex substances, improving odor differentiation, compensating for sensor drift, and ensuring real-world reliability. These limitations indicate that a complete device mimicking the flexibility and selectivity of the human olfactory system is not yet available. To address these gaps, our review recommends solutions such as the adoption of adaptive machine learning models to reduce calibration needs and enhance drift resilience and the implementation of standardized protocols for data acquisition and model validation. We introduce benchmark comparisons and a future roadmap for electronic noses that demonstrate their potential to evolve from controlled studies to scalable industrial applications. In doing so, this review aims not only to assess the state of the field but also to support its transition toward more robust, interpretable, and field-ready electronic nose technologies.

30 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
AYAroosa Younis Younis
Aroosa Younis Younis
ASAdeeb Shehzad
Adeeb Shehzad
SISalman Ul Islam
Salman Ul Islam
EAEbtesam Abdullah Al-Suhaimi
Ebtesam Abdullah Al-Suhaimi
YLYoung-Sup Lee
Young-Sup Lee
Malaria is a parasitic infection caused by bites from Plasmodium falciparum (P. falciparum)-infected mosquitoes with a present scale of symptoms ranging from moderate fever to neurological disorders. P. falciparum is the most lethal of the five strains of malaria, and is a major case of morbidity and mortality in endemic regions. Recent advancements in malaria diagnostic tools and prevention strategies have improved conjugation antimalarial therapies using fumigation and long-lasting insecticidal sprays, thus lowering malarial infections. Declines in the total number of infected individuals have been correlated with antimalarial drugs. Despite this, malaria remains a major health threat, affecting more than 30 million men, women, and children around the globe, and 20 percent of all children around the globe have malaria parasites in their blood. To overcome this life-threatening condition, novel therapeutic strategies, including immunization, are urgently needed to tackle this infection around the world. In line with this, the development of the RTS, S vaccine was a significant step forward in the fight against malaria. RTS, S is a vaccine for P. falciparum in which R specifies central repeat units, T the T-cell epitopes, and S indicates surface antigen. The RTS, S/AS01 malarial vaccine was synthesized and screened in several clinical trials between 2009 and 2014, involving thousands of young children in seven African countries, showing that children who received the vaccine did not suffer from severe malaria. Mosquirix™ was approved by the World Health Organization in 2021, indicating it to be safe and advocating its integration into routine immunization programs and existing malaria control measures. This paper examines the various stages of the vaccine’s development, including the evaluation of its immunogenicity and efficacy on the basis of a total of 2.3 million administered doses through a routine immunization program. The protection and effectiveness provided by the vaccine are strong, and evidence shows that it can be effectively delivered through the routine child immunization platform. The economic cost of the vaccine remains to be considered.

11 September 2023 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
MOHAMMAD AZAM ANSARIMOHAMMAD AZAM ANSARI
MOHAMMAD AZAM ANSARI
WCWaseem Chauhan
Waseem Chauhan
SSShoaib Shoaib
Shoaib Shoaib
SASami A. Alyahya
Sami A. Alyahya
MAMubashshir Ali
Mubashshir Ali
EAEbtesam Abdullah Al-Suhaimi
Ebtesam Abdullah Al-Suhaimi